Pharma majors join hands for Molnupiravir trial for Covid-19 treatment


Leading drug makers Dr Reddy’s Laboratories, Cipla, Emcure Pharmaceuticals, Sun Pharmaceutical Industries and Torrent Pharmaceuticals have decided to collaborate for clinical trial of the investigational oral antiviral drug Molnupiravir for the treatment of mild COVID-19.

The five pharma have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in the country, according to regulatory filings by Dr Reddy’s and Cipla.

As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, Dr Reddy’s will conduct the clinical trial using its product, and the other four pharma will be required to demonstrate equivalence of their product to the product used by Dr Reddy’s in its clinical trial, the filings noted.

The clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting and is expected to take place between June and September across India with the recruitment of 1,200 patients, they added.

Such collaboration for a clinical trial is a first of its kind within the industry, and will aim to investigate yet another line of treatment in the collective fight against the COVID-19 pandemic, the noted.

On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply Molnupiravir for the treatment of COVID-19 in India, it added.

Molnupiravir is an oral antiviral drug that inhibits the replication of multiple RNA viruses including SARS-CoV-2.

It is currently being studied by MSD, through a collaboration with Ridgeback Biotherapeutics, in a Phase Ill trial for the treatment of non-hospitalised patients with confirmed COVID-19 globally.

Between March and April this year, the five companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low- and middle-income countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *